We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

94 hedge funds and large institutions have $357M invested in KalVista Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more capital invested

Capital invested by funds: $237M → $357M (+$120M)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

5.38% more ownership

Funds ownership: 98.85% → 104.23% (+5.4%)

3% more funds holding

Funds holding: 91 → 94 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 31

Holders
94
Holders Change
+3
Holders Change %
+3.3%
% of All Funds
1.62%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
15
Increased
29
Reduced
31
Closed
12
Calls
$9.88M
Puts
–
Net Calls
+$9.88M
Net Calls Change
+$3.88M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$12M
2
DCM
Driehaus Capital Management
Illinois
+$7.4M
3
Millennium Management
Millennium Management
New York
+$5.28M
4
IBT
International Biotechnology Trust
United Kingdom
+$4.37M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.28M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$4.67M
2
PM
Prosight Management
Texas
-$4.06M
3
SCM
Suvretta Capital Management
New York
-$3.09M
4
LCM
Laurion Capital Management
New York
-$1.72M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
76
Tower Research Capital (TRC)
New York
$29K -$2.31K -165 -8%
AIP
77
Ameritas Investment Partners
Nebraska
$22K – – –
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
$19.9K – – –
Rockefeller Capital Management
79
Rockefeller Capital Management
New York
$19K – – –
UBS Group
80
UBS Group
Switzerland
$18K +$2.35K +168 +16%
O
81
OrbiMed
New York
$15.1K +$12M +856,600 +462%
Russell Investments Group
82
Russell Investments Group
United Kingdom
$14K +$14K +1,004 New
Citigroup
83
Citigroup
New York
$10K -$20.7K -1,478 -69%
S
84
SignatureFD
Georgia
$8K +$7.66K +548 New
TWA
85
TCI Wealth Advisors
Arizona
$5K – – –
CUAMC
86
China Universal Asset Management Company
China
$3K +$3.21K +230 New
CS
87
Credit Suisse
Switzerland
$2K +$1.58K +113 +471%
Daiwa Securities Group
88
Daiwa Securities Group
Japan
$1K – – –
LC
89
Lindbrook Capital
California
$1K +$587 +42 New
Marshall Wace
90
Marshall Wace
United Kingdom
– -$1.32M -133,687 Closed
HF
91
HRT Financial
New York
– -$676K -68,778 Closed
TI
92
Trexquant Investment
Connecticut
– -$384K -39,048 Closed
Two Sigma Investments
93
Two Sigma Investments
New York
– -$369K -37,453 Closed
First Trust Advisors
94
First Trust Advisors
Illinois
– -$306K -31,129 Closed
EGM
95
Engineers Gate Manager
New York
– -$165K -16,721 Closed
PP
96
PDT Partners
New York
– -$139K -14,113 Closed
DTL
97
Dynamic Technology Lab
Singapore
– -$137K -13,969 Closed
QT
98
Quantbot Technologies
New York
– -$34K -3,500 Closed
PHK
99
Point72 Hong Kong
Hong Kong
– -$26K -2,646 Closed
Simplex Trading
100
Simplex Trading
Illinois
– -$8.06K -577 Closed
1 2 3
4
5

KALV Hedge Fund Activity: Q3 2022 in Review

94 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2022, worth a combined $357M — up 50% from $237M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KALV positions and 12 closed out — a net gain of 3 holders — while 29 added to existing stakes and 31 trimmed.

The largest buyer was OrbiMed, adding an estimated $12M. The largest seller was Woodline Partners, cutting an estimated $4.67M.

  • 94 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2022, up from 91 in Q2 2022.
  • Funds reported $357M of KalVista Pharmaceuticals stock for Q3 2022, up 50% quarter-over-quarter.
  • 15 funds opened new KalVista Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +3 holders.
  • The largest KalVista Pharmaceuticals buyer in Q3 2022 was OrbiMed, an estimated $12M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2022 was Woodline Partners, an estimated $4.67M sold.

Based on aggregated 13F filings for Q3 2022.